Extended Data Fig. 9: Design of the microfluidic DNA chip and of the control processes.
a, Schematic of point-of-care FEMMAN DNA-chip. b, the front (left) and back (right) schematics. c, Control processes design. The initial state of valves 1 and 2 are closed while valve 3 is opened (1). In (2), valve 1 was opened, valves 2 and 3 were closed, and the liquid in chamber a is sucked into chamber c. In (3), valve 1, 2 and 3 were closed. In (4), valve 2 was opened, the 1 and 3 were closed, liquid in chamber b was sucked into the chamber c and mixed with the liquid in chamber c. In (5), valve 3 was open, valves 1 and 2 were closed, and the liquid in chamber c was driven into chamber d and incubated for 1 h at room temperature. In (6), valve 3 was opened, valves 1 and 2 were closed, the peristaltic pump drives the washing buffer to wash the DNA-chip in chamber d, and finally, the waste flowed into the waste chamber e. d, Schematic of synthesis processes for microfluidic DNA chip. e, FEMMAN point-of-care device realized 100 copies/rxn (10 copies/µL) lentivirus detection using fluorescence requisition system. f, Schematic of array on DNA-chip in point-of-care device. g, Image of 100 copies/rxn (10 copies/µL) lentivirus detection using fluorescence requisition system in tool-box sized portable device. SARS-CoV-2 detection at 100 copies/rxn (10 copies/µL) can be clearly visualized by the fluorescence acquisition system. h, Images of point-of-care device and automated microfluidic DNA chip.
